Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 81,682 shares traded hands during mid-day trading, a decline of 39% from the previous session's volume of 134,133 shares.The stock last traded at $9.37 and had previously closed at $9.18.
Cybin Stock Up 4.9 %
The stock has a market cap of $3.96 billion, a PE ratio of -45.86 and a beta of 0.50.
Cybin (NYSEAMERICAN:CYBN - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter. Analysts forecast that Cybin Inc. will post -0.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cybin stock. Rathbones Group PLC bought a new stake in shares of Cybin Inc. (NYSEAMERICAN:CYBN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 65,381 shares of the company's stock, valued at approximately $26,000. Institutional investors own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
